Advertisement

Peripheral neuropathy due to vasculitis: immunopathogenesis, clinical features and treatment

  • J. T. Kissel
  • J. R. Mendell
Part of the Immunology and Medicine Series book series (IMME, volume 24)

Abstract

In the 15 years that have elapsed since the publication of Fauci et al.’s seminal view on vasculitis1, there has been significant growth in our understanding of this enigmatic group of disorders. Advances in basic and clinical research have resulted in new concepts concerning the aetiology, immunology, and pathophysiology of the vasculitides, and new proposals for the diagnosis and classification of these diseases. More importantly, new and innovative therapies have been proposed based on current formulations of the immunopathogenesis of the blood vessel damage. Most of this information is immediately relevant for the practising clinician, who is faced with the formidable task of diagnosing and treating these difficult patients. This review will summarize our current understanding of vasculitis affecting the peripheral nervous system and outline the diagnosis and clinical management of these patients.

Keywords

Giant Cell Arteritis Systemic Vasculitis Neuromuscular Disease Temporal Arteritis Superficial Peroneal Nerve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis. Clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med. 1978;89:660–76.PubMedGoogle Scholar
  2. 2.
    Cupps TR, Fauci AS. The vasculitides. In: Smith LM, ed. Major problems in internal medicine. Vol. 21. Philadelphia: WB Saunders, 1981:6–19.Google Scholar
  3. 3.
    Hunder GG, Arend WP, Block DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum. 1990;33:1065–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Bloch DA, Michel BA, Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum. 1990;33:1068–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Moore PM, Cupps TR. Neurologic complications of vasculitis. Ann Neurol. 1983;14: 155–67.PubMedCrossRefGoogle Scholar
  6. 6.
    Cohen SB, Hurd ER. Neurological complications of connective tissue and other ‘collagen-vascular’ diseases. Semin Arthritis Rheum. 1981;11:190–212.PubMedCrossRefGoogle Scholar
  7. 7.
    Moore PM, Fauci AS. Neurologic manifestations of systemic vasculitis. A retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients. Am J Med. 1981;71:517–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Sigal LH. The neurologic presentation of vasculitis and rheumatologic syndromes. Medicine. 1987;66:157–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Kissel JT, Slivka AP, Warmolts JR, et al. The clinical spectrum of necrotizing angiopathy of the peripheral nervous system. Ann Neurol. 1985;18:251–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain. 1987;110:843–54.PubMedCrossRefGoogle Scholar
  11. 11.
    Hawke SHB, Davies L, Pamphlett R, Guo Y-P, Pollard JD, McLeod JG. Vasculitic neuropathy. A clinical and pathological study. Brain. 1991;114:2175–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Smiley JD, Moore M. Immune complex vasculitis: role of complement and IgG-Fc receptor functions. Am J Med Sci. 1989;298:267–77.PubMedCrossRefGoogle Scholar
  13. 13.
    McDougal JS, McDuffie FC. Immune complexes in man: detection and clinical significance. Adv Clin Chem. 1985;24:1–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Cornacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest. 1983;71:236–47.PubMedCrossRefGoogle Scholar
  15. 15.
    Becherer JD, Alsenz J, Servic C, et al. Cell surface proteins reacting with activated complement components. Complement Inflamm. 1989;6:142–65.PubMedGoogle Scholar
  16. 16.
    Fauci AS. The vasculitic syndromes. In: Wilson JD, Braunwald E, Issellbacher KJ, et al. (eds). Harrison’s Principles of Internal Medicine. New York: McGraw Hill, 1991;1456–63.Google Scholar
  17. 17.
    Savage COS, Ng YC. The aetiology and pathogenesis of major systemic vasculitides. Postgrad Med J. 1986;62:627–36.PubMedCrossRefGoogle Scholar
  18. 18.
    Hogg N. The structure and function of Fe receptors. Immunol Today. 1988;9:185–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Moore PM. Immune mechanisms in the primary and secondary vasculitides. J Neurol Sci. 1989;93:129–45.PubMedCrossRefGoogle Scholar
  20. 20.
    Kissel JT, Riethman JL, Omerza J, et al. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol. 1989;25:291–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;4:875–80.Google Scholar
  22. 22.
    Ryan US. The endothelial surface and responses to injury. Fed Proc. 1986;45:101–8.PubMedGoogle Scholar
  23. 23.
    Pangyres PK, Blumbergs PC, Leong AS-Y, Bourne AJ. Vasculitis of peripheral nerve and skeletal muscle: clinicopathological correlation and immunopathic mechanisms. J Neurol Sci. 1990;100:193–202.CrossRefGoogle Scholar
  24. 24.
    Pober JS, Cotran R. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427–51.PubMedGoogle Scholar
  25. 25.
    Cavender DE. Organ-specific and non-organ-specific lymphocyte receptors for vascular endothelium. J Invest Dermatol. 1990;94(suppl.):41–85.CrossRefGoogle Scholar
  26. 26.
    Brasile L, Kremer JM, Clarke JL. Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis. Am J Med. 1989;87:74–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Frampton G, Jayne DRW, Perry GJ et al. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol. 1990;82:227–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Editorial. Antibodies to endothelial cells. Lancet. 1991;337:649–50.CrossRefGoogle Scholar
  29. 29.
    Gaskin G, Savage COS. Immune markers in vasculitis. Br J Hosp Med. 1991;46:104–6.PubMedGoogle Scholar
  30. 30.
    Ferraro G, Meroni PL, Tincani A et al. Anti-endothelial cell antibodies in patients with Wegener’s granulomatosis and micropolyarteritis. Clin Exp Immunol. 1990;79:47–53.PubMedCrossRefGoogle Scholar
  31. 31.
    Goeken JA. Antineutrophil cytoplasmic antibody - a useful serological marker for vasculitis. 7 Clin Immunol. 1991;11:161–74.Google Scholar
  32. 32.
    Parlevliet KJ, Henzen-Logmans SC, Oe PL, et al. Antibodies to components of neutrophil cytoplasm: a new diagnostic tool in patients with Wegener’s granulomatosis and systemic vasculitis. Q J Med. 1988;66:55–63.PubMedGoogle Scholar
  33. 33.
    Egner W, Chapel HM. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol. 1990;82: 244–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Lai KN, Jayne DRW, Brownlee A, Lockwood CM. The specificity of anti-neutrophil cytoplasm antibodies in systemic vasculitides. Clin Exp Immunol. 1990;82:233–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Bleil L, Manger B, Winkler TH, et al. The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. J Rheumatol. 1991;18:1199–206.PubMedGoogle Scholar
  36. 36.
    Ewert BH, Jennette JC, Falk RJ. The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis. 1991;18:188–95.PubMedGoogle Scholar
  37. 37.
    Nolte B, Specks U, Liidemann J et al. Anticytoplasmic antibodies: their immunodiagnostic value in Wegener’s granulomatosis. Ann Intern Med. 1989;111:28–40.Google Scholar
  38. 38.
    Panegyres PK, Faull RJ, Russ GR, Appleton SL, Wangel AG, Blumbergs PC. Endothelial cell activation in vasculitis of peripheral nerve and skeletal muscle. J Neurol Neurosurg Psychiatry. 1992;55:4–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Shuki H, Shimokama T, Watanabe T. Temporal arteritis. Cell composition and the possible pathogenetic role of cell-mediated immunity. Hum Pathol. 1989;20:1057–64.CrossRefGoogle Scholar
  40. 40.
    Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener’s granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med. 1983;74:700–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Grau GE, Roux-Lombard P, Gysler C et al. Serum cytokine changes in systemic vasculitis. Immunology. 1989;68:196–8.PubMedGoogle Scholar
  42. 42.
    Grau GE, Piguet PF, Vassalli P, Lambert PH. Involvement of tumour necrosis factor and other cytokines in immune-mediated vascular pathology. Int Arch Allergy Appl Immunol. 1989;88:34–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Braquet P, Hosford D, Braquet M, et al. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol. 1989;88:88–100.PubMedCrossRefGoogle Scholar
  44. 44.
    Mancardi GL, Cadoni A, Zicca A et al. HLA-DR Schwann cell reactivity in peripheral neuropathies of different origins. Neurology. 1988;38:848–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Nukada H, Dyck PJ. Acute ischemia causes axonal stasis, swelling, attenuation and secondary demyelination. Ann Neurol. 1987;22:311–18.PubMedCrossRefGoogle Scholar
  46. 46.
    Said G, Laxroix-Ciaudo C, Fujimura H et al. The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol. 1988;23:461–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Fujimura H, Lacroix C, Said G. Vulnerability of nerve fibers to ischaemia. A quantitative light and electron microscope study. Brain. 1991;114:1929–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Dyck P, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy: three-dimensional morphology of fiber degeneration related to sites of occluded vessels. Mayo Clin Proc. 1972;47:461–75.PubMedGoogle Scholar
  49. 49.
    Wees SJ, Sunwoo IN, Oh SJ. Sural nerve biopsy in systemic necrotizing vasculitis. Am J Med. 1981;71:525–32.Google Scholar
  50. 50.
    Harati Y, Niakan E. The clinical spectrum of inflammatory-angiopathic neuropathy. J Neurol Neurosurg Psychiatry. 1986;49:1313–16.CrossRefGoogle Scholar
  51. 51.
    Bouche P, Leger JM, Travers MA et al Peripheral neuropathy in systemic vasculitis: clinical and electrophysiologic study of 22 patients. Neurology. 1986;36:1598–602.PubMedCrossRefGoogle Scholar
  52. 52.
    Olney RK. Neuropathies in connective tissue disease. Muscle Nerve. 1992;15:531–42.PubMedCrossRefGoogle Scholar
  53. 53.
    Ropert A, Metral S. Conduction block in neuropathies with necrotizing vasculitis. Muscle Nerve. 1990;13:102–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Jamieson PW, Guiliani MJ, Martinez AJ. Necrotizing angiopathy presenting with multifocal conduction blocks. Neurology. 1991;41:442–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Kissel JT, Mendell JR. Vasculitic neuropathy. Neurol Clin. 1992;10:761–81.PubMedGoogle Scholar
  56. 56.
    Scott DGI. Classification and treatment of systemic vasculitis. Br J Rheumatol. 1988;27: 251–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Haynes BF, Allen NB, Fauci AS. Diagnostic and therapeutic approach to the patient with vasculitis. Med Clin North Am. 1986;70:355–68.PubMedGoogle Scholar
  58. 58.
    Axelrod L. Glucocorticoids. In: Kelley WN, Harris ED, Ruddy S et al., editors. Textbook of Rheumatology. New York: WB Saunders, 1989;845–61.Google Scholar
  59. 59.
    Dalakas M. Pharmacologic concerns of corticosteroids in the treatment of patients with immune-related neuromuscular diseases. Neurol Clin. 1990;8:93–118.PubMedGoogle Scholar
  60. 60.
    Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Eng] J Med. 1992;326: 1473–9.CrossRefGoogle Scholar
  61. 61.
    Stillwell TJ, Benson RC, DeRemee RA et al. Cyclophosphamide-induced bladder toxicity in Wegener’s granulomatosis. Arthritis Rheum. 1988;31:465–70.PubMedCrossRefGoogle Scholar
  62. 62.
    Katz P, Fauci AS. Immunosuppressives and immunoadjuvants. In: Samter M, Talmage DW, Frank MM et al., editors, Immunological Disease. Boston: Little Brown, 1988: 675–98.Google Scholar
  63. 63.
    Kisel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology. 1986;36:35–9.CrossRefGoogle Scholar
  64. 64.
    Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Kissel JT, Rammohan KW. Pathogenesis and therapy of nervous system vasculitis. Clin Neuropharmacol. 1991;14:28–48.PubMedCrossRefGoogle Scholar
  66. 66.
    Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301:235–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Leib ES, Restivo C, Paulus HE Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med. 1979;67:941–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Fauci AS, Haynes BF, Katz P et al. Wegener’s granulomatosis: prospective and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76–85.PubMedGoogle Scholar
  69. 69.
    Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer. 1991;68:1430–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Schwartz SA. Intravenous immunoglobulin (IVIG) in the therapy of autoimmune disorders. J Clin Immunol. 1990;10:81–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107–16.PubMedCrossRefGoogle Scholar
  72. 72.
    Jaynes DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991;337:1137–9.CrossRefGoogle Scholar
  73. 73.
    Conn DL. Update on systemic necrotizing vasculitis. Mayo Clin Proc. 1989;64:535–43.PubMedGoogle Scholar
  74. 74.
    Huse WD, Lakshmi S, Iverson SA et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989;246:1275–81.PubMedCrossRefGoogle Scholar
  75. 75.
    Mathieson PW, Cobbold SP, Hale G et al. Monoclonal antibody therapy in systemic vasculitis. N Engl J Med. 1990;323:250–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • J. T. Kissel
  • J. R. Mendell

There are no affiliations available

Personalised recommendations